Estring Shortage: What Providers and Prescribers Need to Know in 2026

Estring (estradiol vaginal ring, Pfizer) has faced documented supply disruptions and continues to present availability challenges for patients in 2026. This post provides a clinical overview for gynecologists, primary care providers, NPs, PAs, and other prescribers managing postmenopausal patients who rely on this therapy.

Clinical Background: What Estring Is and Who Uses It

Estring is an FDA-approved local estrogen therapy delivering approximately 7.5 mcg/day of estradiol over 90 days via a soft, flexible vaginal ring. It is indicated for moderate to severe vulvar and vaginal atrophy (VVA) / genitourinary syndrome of menopause (GSM), including symptoms of vaginal dryness, burning, irritation, dyspareunia, and urinary urgency.

Because of its low systemic absorption, Estring is generally considered a first-line option for patients who require local estrogen therapy — including some patients with a history of estrogen-sensitive conditions when prescribed with appropriate risk-benefit discussion. The 90-day delivery interval is a significant adherence advantage for patients compared to twice-weekly tablet or cream regimens.

Shortage History and Current Supply Status

The ASHP documented an official Estring shortage beginning February 2024, caused by manufacturing delays at Pfizer. The shortage was updated to "available" in May 2024. However, pharmacy-level availability has remained inconsistent due to:

Ongoing distribution normalization post-shortage across regional wholesalers

Surge in HRT prescriptions following the FDA's November 2025 removal of the black box warning from systemic menopausal hormone therapies

No generic alternative — Pfizer is the sole U.S. manufacturer

Clinicians should anticipate that some patients will present reporting inability to fill their Estring prescription, even without an active FDA shortage.

Therapeutic Alternatives: Clinical Comparison

When Estring is unavailable, the following local vaginal estrogen therapies are appropriate alternatives for most GSM patients:

Estradiol Vaginal Tablets (Vagifem / Yuvafem / generic)

Estradiol 10 mcg vaginal tablets offer a convenient twice-weekly maintenance regimen after initial daily loading for 2 weeks. Generic estradiol vaginal tablets (equivalent to Vagifem) are widely available and significantly more affordable. This is typically the easiest substitution to make — the hormone and mechanism of action are identical to Estring; only the delivery system changes.

Prescribing note: Prescribe as "estradiol vaginal tablet 10 mcg — insert 1 tablet vaginally daily x 2 weeks, then twice weekly." Generic is available and preferred for cost.

38,518+ patients found their medications in stock

38K+

Find Estring In Stock Today →

Estradiol Vaginal Cream (Estrace / generic)

Estradiol 0.01% vaginal cream (Estrace or generic) is another widely available option. Starting dose is typically 2–4 g nightly for 1–2 weeks, then 1 g twice weekly. Generic is available and affordable. Some patients prefer cream for the additional moisturizing effect; others find the applicator less convenient than a ring or tablet.

Premarin Vaginal Cream (Conjugated Estrogens)

Premarin Vaginal Cream (conjugated estrogens 0.625 mg/g) is an appropriate alternative, particularly if patients have historically responded well to conjugated estrogen products. Clinical studies comparing Estring and Premarin Vaginal Cream showed similar efficacy in reducing vaginal pH and improving maturation index. Brand-only; no generic is available.

Skip the calls, skip the stress.

Find Estring In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Imvexxy (Estradiol Vaginal Softgel Inserts)

Imvexxy delivers 4 mcg or 10 mcg of estradiol in a coconut oil-based softgel. It is the lowest-dose approved vaginal estrogen and may be preferred for patients in whom you want to minimize any systemic exposure. FDA-approved for moderate to severe dyspareunia. Brand-only; manufacturer assistance programs available.

Prasterone / Intrarosa (Non-Estrogen Option)

Prasterone (DHEA, Intrarosa) 6.5 mg vaginal insert is an appropriate option for patients who cannot or prefer not to use estrogen. It acts as a local androgen and estrogen precursor within vaginal tissue. Approved for dyspareunia due to menopause. Daily insertion required. Consider for patients with personal or family history of hormone-sensitive cancers.

Compounding Pharmacy Considerations

Compounding pharmacies can prepare vaginal estradiol formulations (creams, suppositories, rings) when commercial products are unavailable. However, compounded hormone therapies are not FDA-approved and lack the standardized bioavailability data of commercial products. If you refer patients to a compounding pharmacy, ensure it is PCAB-accredited and provides appropriate documentation of compounding practices.

Patient Communication Guidance

When counseling patients affected by Estring supply challenges:

Reassure patients that multiple effective alternatives exist — Estring is not the only option

Explain that a switch to vaginal tablets or cream does not mean inferior therapy — efficacy is comparable

Consider writing a bridge prescription proactively if a patient is approaching end of ring cycle and local shortage is likely

Recommend patients use medfinder to locate which pharmacies currently have Estring before assuming it's unavailable everywhere

Helping Your Patients Find Estring

For patients who specifically need Estring and want help finding a pharmacy that has it, medfinder for providers offers a tool to help your patients locate which pharmacies near them can fill the prescription — without spending hours on hold. Sharing this resource with your patients saves them time and reduces the likelihood of treatment interruption.